Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | APLNR | P35414 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4191651 | 1.00 | CA2 (0.47) | CA2APLNRTP53MAPTCYP1A2 | |
| SCHEMBL4190771 | 1.00 | CA2 (0.47) | CA2APLNRTP53MAPTCYP1A2 | |
| SCHEMBL14510201 | 0.87 | CA2 (0.48) | CA2SLC2A1 | |
| SCHEMBL5734584 | 0.87 | CA2 (0.40) | CA2APLNRCYP1A2CYP2D6ALDH1A1 | |
| SCHEMBL5732344 | 0.86 | CA2 (0.39) | CA2APLNRALDH1A1SLC6A4KDM4E | |
| SCHEMBL8695498 | 0.86 | CA2 (0.50) | CA2MAPTCYP1A2SLC2A1ALDH1A1 | |
| SCHEMBL8694969 | 0.85 | CA2 (0.49) | CA2MAPTALDH1A1 | |
| SCHEMBL1471822 | 0.83 | CA2 (0.46) | CA2SLC2A1 | |
| SCHEMBL1471675 | 0.83 | CA2 (0.46) | CA2SLC2A1 | |
| SCHEMBL9645914 | 0.82 | CA2 (0.35) | CA2APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2027081-B1 | THERAPEUTIC PROSTAGLANDIN COMPOUNDS FOR THE TREATMENT OF GLAUCOMA | ALLERGAN INC (US) | 2017-05-03 | — | — | EP | disclosed |
| EP-2888250-A1 | PROCESS FOR THE SYNTHESIS OF SUBSTITUTED GAMMA LACTAMS | ALLERGAN, INC. (US) | 2015-07-01 | — | — | EP | disclosed |
| WO-2014031581-A1 | PROCESS FOR THE SYNTHESIS OF SUBSTITUTED GAMMA LACTAMS | ALLERGAN, INC. (US) | 2014-02-27 | — | — | WO | disclosed |
| EP-1819670-B1 | 12-ARYL PROSTAGLANDIN ANALOGS | ALLERGAN INC (US) | 2012-08-08 | — | — | EP | disclosed |
| US-8198318-B2 | Therapeutic amides | ALLERGEN, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-7985767-B2 | Glaucoma or ocular hypertension; selective prostaglandin EP2 agonists; carboxy-functional amides or sulfonamide and carboxy bioisosteres thereof; 5-(-3-(N-(4-(1-hydroxyhexyl)phenyl)acetamido)butyl)thiophene-2-carboxylic acid for example | ALLERGAN, INC. (US) | 2011-07-26 | — | — | US | disclosed |
| US-7964596-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-7964634-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-7956055-B2 | Substituted gamma lactams as therapeutic agents | ALLERGAN, INC. (US) | 2011-06-07 | — | — | US | disclosed |
| US-7915316-B2 | Sulfonamides | ALLERGAN, INC (US) | 2011-03-29 | — | — | US | disclosed |
| US-20080045596-A1 | Ep2 Receptor Agonists | ASTERAND, INC. | 2008-02-21 | — | — | US | disclosed |
| US-20070293551-A1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | ALLERGAN | 2007-12-20 | — | — | US | disclosed |
| US-20070281981-A1 | Glaucoma; 3-substituted pyrrolidine compounds; prostaglandin receptor modulators | ALLERGAN, INC. | 2007-12-06 | — | — | US | disclosed |
| WO-2007115020-A2 | THERAPEUTIC PROSTAGLANDIN COMPOUNDS FOR THE TREATMENT OF GLAUCOMA | ALLERGAN, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
| US-20070142471-A1 | SULFONAMIDES | ALLERGAN, INC. | 2007-06-21 | — | — | US | disclosed |
| US-20070129552-A1 | Therapeutic Substituted Cyclopentanes | ALLERGAN, INC. | 2007-06-07 | — | — | US | disclosed |
| US-20070129552-A1 | Therapeutic Substituted Cyclopentanes | ALLERGAN, INC. | 2007-06-07 | — | — | US | disclosed |
| EP-1716113-A1 | EP2- RECEPTOR AGONISTS | ASTERAND UK LIMITED (GB) | 2006-11-02 | — | — | EP | disclosed |
| US-20050209336-A1 | EP2 receptor agonists | ASTERAND, INC. | 2005-09-22 | — | — | US | disclosed |
| WO-2005061449-A1 | EP2 RECEPTOR AGONISTS | PHARMAGENE LABORATORIES LIMITED (GB) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209336-A1 | EP2 receptor agonists | PTGER2, PTGER1, PTGER3 | CA2 875/4885APLNR 264/4885TP53 3557/4885 |
| US-20070281981-A1 | Glaucoma; 3-substituted pyrrolidine compounds; prostaglandin receptor modulators | PTGIR, PTGIS, PTGS1 | CA2 404/4885APLNR 938/4885TP53 2708/4885 |
| US-20070293551-A1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | GLA, GUSB, GANAB | CA2 1634/4885APLNR 4060/4885TP53 2442/4885 |
| US-20070142471-A1 | SULFONAMIDES | CRYZ, QDPR, GLRX3 | CA2 625/4885APLNR 1568/4885TP53 4845/4885 |
| US-20070129552-A1 | Therapeutic Substituted Cyclopentanes | MCL1, GLI1, BID | CA2 3801/4885APLNR 792/4885TP53 53/4885 |
| US-20080045596-A1 | Ep2 Receptor Agonists | PTGER2, PTGER1, PTGER3 | CA2 875/4885APLNR 264/4885TP53 3557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.